1. Home
  2. LYRA

as 06-06-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medical/Dental Instruments

Nasdaq

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Founded: 2005 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 5.8M IPO Year: 2020
Target Price: $100.00 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -60.66 EPS Growth: N/A
52 Week Low/High: $3.81 - $37.50 Next Earning Date: 05-06-2025
Revenue: $1,185,000 Revenue Growth: -29.46%
Revenue Growth (this year): -23.66% Revenue Growth (next year): 1286.17%

LYRA Daily Stock ML Predictions

Share on Social Networks: